This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Credit Markets Aren't Stopping Health Care M&A

Tight credit markets haven't stopped health care M&A, and last week offered up another interesting chapter that involved three long picks from the Biotech Select portfolio.

Merck (MRK - Get Report) said it will link up with its cholesterol drug partner Schering-Plough (SGP), and Roche finally -- finally -- found mutual terms with Genentech (DNA), one of those long positions.

Biotech Select portfolio manager Adam Feuerstein says Genentech's blessing is enough to convince the minority shareholders to approve the deal, but what will Roche have to do to get Genentech's talent to stay?

Meanwhile, two other long picks in the Biotech Select portfolio made merger news, as well. Gilead (GILD - Get Report) said Thursday that it is picking upCV Therapeutics (CVTX) in a $1.4 billion deal.

Roche-Genentech was a long time coming, but just one of many matches made in health care recently. Not so long ago, Eli Lilly (LLY) bought ImClone and Pfizer (PFE - Get Report) recently said it would acquire Wyeth (WYE).

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GILD $88.21 0.00%
MRK $54.84 0.00%
PFE $32.71 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs